Cel-Sci Corporation stock is up 14.1% since 30 days ago. The next earnings date is Dec 26, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 18.52% of the previous 26 December’s closed higher than November.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.